In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD ... becomes more evident when compared to its rival, Amgen Inc. (AMGN), which gained 14.4% over the past 52 weeks and 21.5 ...

BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ ...

This raises an important question: Are these moves into overbought conditions a signal of potential exhaustion, suggesting ...

The Latest research report offers an in-depth analysis of the Healthcare Nanotechnology Market, highlighting key trends in product segmentation, company dynamics, revenue streams, market share, recent ...

We provide more details on some of the top companies in the Nasdaq 100 index that are dragging the QQQ ETF this year.

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors ...